Jose Manuel Otero

CIK: 0002024096

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)9 (52.9%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)8 (47.1%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

LXEO

Lexeo Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (17 total)

LXEO
Lexeo Therapeutics, Inc.
Sep 24, 2026
Award(A)
Stock Option (right to buy)
Direct
54.8K shares-
LXEO
Lexeo Therapeutics, Inc.
Sep 14, 2026
Award(A)
Direct
2.1K shares at avg. $2.64$6K
LXEO
Lexeo Therapeutics, Inc.
Aug 18, 2026
Sale(S)
Direct
1.3K shares at avg. $4.96$6K
LXEO
Lexeo Therapeutics, Inc.
Jul 1, 2026
Sale(S)
Direct
4.7K shares at avg. $4.48$21K
LXEO
Lexeo Therapeutics, Inc.
Jun 29, 2026
Award(A)
Direct
12.1K shares-
LXEO
Lexeo Therapeutics, Inc.
May 18, 2026
Sale(S)
Direct
1.3K shares at avg. $5.07$7K
LXEO
Lexeo Therapeutics, Inc.
Mar 13, 2026
Award(A)
Direct
5.9K shares at avg. $2.64$16K
LXEO
Lexeo Therapeutics, Inc.
Feb 18, 2026
Sale(S)
Direct
3K shares at avg. $6.40$19K
LXEO
Lexeo Therapeutics, Inc.
Feb 4, 2026
Award(A)
Direct
65K shares-
LXEO
Lexeo Therapeutics, Inc.
Nov 18, 2025
Sale(S)
Direct
721 shares at avg. $9.27$7K
LXEO
Lexeo Therapeutics, Inc.
Oct 17, 2025
Sale(S)
Direct
2.1K shares at avg. $8.94$19K
LXEO
Lexeo Therapeutics, Inc.
Oct 17, 2025
Sale(S)
Direct
24 shares at avg. $9.56$229.464
LXEO
Lexeo Therapeutics, Inc.
Oct 15, 2025
Award(A)
Direct
5.9K shares-
LXEO
Lexeo Therapeutics, Inc.
Aug 18, 2025
Sale(S)
Direct
721 shares at avg. $9.27$7K
LXEO
Lexeo Therapeutics, Inc.
Aug 18, 2025
Sale(S)
Direct
2.8K shares at avg. $4.67$13K
LXEO
Lexeo Therapeutics, Inc.
Mar 14, 2025
Award(A)
Direct
5.7K shares at avg. $2.61$15K
LXEO
Lexeo Therapeutics, Inc.
Jan 7, 2025
Award(A)
Direct
26.3K shares-

		Type	Shares	Price		Ownership
Sep 24, 2026	LXEO Lexeo Therapeutics, Inc.	Award(A) Stock Option (right to buy)	54,750	-	-	Direct
Sep 14, 2026	LXEO Lexeo Therapeutics, Inc.	Award(A)	2,110	$2.64	$5,579	Direct
Aug 18, 2026	LXEO Lexeo Therapeutics, Inc.	Sale(S)	1,304	$4.96	$6,464	Direct
Jul 1, 2026	LXEO Lexeo Therapeutics, Inc.	Sale(S)	4,666	$4.48	$20,904	Direct
Jun 29, 2026	LXEO Lexeo Therapeutics, Inc.	Award(A)	12,060	-	$0	Direct
May 18, 2026	LXEO Lexeo Therapeutics, Inc.	Sale(S)	1,302	$5.07	$6,606	Direct
Mar 13, 2026	LXEO Lexeo Therapeutics, Inc.	Award(A)	5,930	$2.64	$15,679	Direct
Feb 18, 2026	LXEO Lexeo Therapeutics, Inc.	Sale(S)	3,016	$6.40	$19,294	Direct
Feb 4, 2026	LXEO Lexeo Therapeutics, Inc.	Award(A)	65,000	-	$0	Direct
Nov 18, 2025	LXEO Lexeo Therapeutics, Inc.	Sale(S)	721	$9.27	$6,684	Direct
Oct 17, 2025	LXEO Lexeo Therapeutics, Inc.	Sale(S)	2,091	$8.94	$18,683	Direct
Oct 17, 2025	LXEO Lexeo Therapeutics, Inc.	Sale(S)	24	$9.56	$229	Direct
Oct 15, 2025	LXEO Lexeo Therapeutics, Inc.	Award(A)	5,940	-	-	Direct
Aug 18, 2025	LXEO Lexeo Therapeutics, Inc.	Sale(S)	721	$9.27	$6,684	Direct
Aug 18, 2025	LXEO Lexeo Therapeutics, Inc.	Sale(S)	2,848	$4.67	$13,294	Direct
Mar 14, 2025	LXEO Lexeo Therapeutics, Inc.	Award(A)	5,720	$2.61	$14,929	Direct
Jan 7, 2025	LXEO Lexeo Therapeutics, Inc.	Award(A)	26,250	-	$0	Direct

1-17 of 17 transactions

About Otero Jose Manuel

Otero Jose Manuel (SEC CIK 0002024096) files insider reports with the SEC as Chief Operating Officer of Lexeo Therapeutics, Inc. (LXEO).

Signal8 holds 13 ownership filings by Otero Jose Manuel, all Form 4s, filed between Jan 10, 2025 and Sep 28, 2026. Those filings report 17 transactions, from Jan 7, 2025 to Sep 24, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Otero Jose Manuel's filings is in NEW YORK, NY.

Recent filings by Otero Jose Manuel

Sep 24, 2026: Grant or award of LXEO derivative securities (Form 4, code A).
Sep 14, 2026: Grant or award of LXEO shares (Form 4, code A).
Aug 18, 2026: Open-market sale of LXEO shares (Form 4, code S).
Jul 1, 2026: Open-market sale of LXEO shares (Form 4, code S).
Jun 29, 2026: Grant or award of LXEO shares (Form 4, code A).

Other insiders filing for Lexeo Therapeutics, Inc. (LXEO)

Tamayo Louis Edward, Chief Financial Officer
Bhalla Narinder Pal, Chief Medical Officer
Townsend Richard Nolan, Chief Executive Officer
Altschuler Steven, Director
Agger Mette Kirstine, Director
COOPERSTONE BRENDA, Director

How to read Form 4 transaction codes